(Q71680431)
Statements
Filgrastim post-chemotherapy mobilizes more CD34+ cells with a different antigenic profile compared with use during steady-state hematopoiesis (English)
Möhle R
Pförsich M
Fruehauf S
Witt B
Krämer A
1 November 1994